Table 3Episodic Migraine—High Quality Evidence for Efficacy by Trial Durationa

Intervention (# of trials)8 Weeks12 Weeks6 Months
Galcanezumab (n=6)1.44 migraine days/month1.83 migraine days/month1.85 migraine days/month
Erenumab (n=5)1.40 migraine days/month1.22 migraine days/month1.84 migraine days/month
Fremanezumab (n=2)—1.35 migraine days/month—
Atopegant (n=1)—1.24 migraine days/month—
Non-invasive vagal nerve stimulation (gammaCore) (n = 1)—0.48 migraine days/month—

These high-quality evidence ratings occurred when selecting the following map filters: “episodic” for migraine, “high” for quality of evidence, and 8, 12, or 6 months for follow-up.

From: Drugs and Devices for Migraine Prevention: Interactive Evidence Maps

Cover of Drugs and Devices for Migraine Prevention: Interactive Evidence Maps
Drugs and Devices for Migraine Prevention: Interactive Evidence Maps [Internet].
Tsou AY, Rouse B, Bloschichak A, et al.
©2021 Patient-Centered Outcomes Research Institute. For more information see www.pcori.org.

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.